Marijuana companies focused on the United States face “massive and unsustainable” valuation discounts relative to their Canadian counterparts, according to a new report.
As of this week, companies with an operational focus on the United States are trading at about 13 times consensus estimates for their 2020 earnings before interest, taxes, depreciation and amortization (EBITDA.)
That represents a 56% discount to the 30 times average for companies focused on Canada, according to Toronto-based Beacon Securities.
The Beacon report noted that U.S.-focused companies have a much larger addressable market than marijuana companies looking to capitalize in Canada.
“They can also offer broader product suites and can participate more fully in the supply chain, which should translate to more sustainable business models with better margin potential,” according to the Beacon report.
The authors concluded that “change is inevitable” as far as marijuana remaining illegal in the U.S..
The Beacon paper said investors in U.S.-focused companies are able to choose between multistate operators and others specializing in coveted markets.
The two major structural advantages the U.S. offers companies over Canada are:
- Product breadth: Additional product forms – edibles, extracts and topicals – will be in short supply in Canada until sometime in 2020, after being permitted later this year.
- Supply-chain participation: Most major markets in Canada (except Quebec) now allow some degree of private-sector retail ownership, but the distribution business is still largely government-controlled, meaning provinces play a large role in setting market prices, and margins, in the regulated industry.
“The U.S. market offers investors multiple, major advantages over the Canadian market,” the report noted.
“Nonetheless, there is a massive valuation gap between them.”
Matt Lamers can be reached at?[email protected]